# Panel and Screen

## I.  Representative Studies 

## II. Biomarker Panel Studies

> [PDFs](https://cloud.tsinghua.edu.cn/d/f72ee6992a1e4ec78044/?p=/Biomarker%20Panel&mode=list)

### 1. Analysis

#### **Differential Expression**

* **circRNA**: _2020 PLOS Comp. Bio._ - seekCRIT: Detecting and characterizing differentially expressed circular RNAs using high-throughput sequencing data

#### **Meta-analysis**

* **protein markers**: 2016 Lancet Neurol - CSF and blood biomarkers for the diagnosis of Alzheimer's disease- a systematic review and meta-analysis
* **DNA markers**: 2014 Nat Genetics - Large-scale genetic study in East Asians identifies six new loci associated with colorectal cancer risk
* **lncRNA markers**: 2005 Cancer Res. - Identification of GATA3 as a Breast Cancer Prognostic Marker by Global Gene Expression Meta-analysis

### 2. Application/Testing

#### Detection/Diagnosis

* **ctDNA+Protein \(CancerSEEK\)**: 2018 - Science - Detection and localization of surgically resectable cancers with a multi-analyte blood test
* **ctDNA+Protein+Clinical Info**: 2019 - PNAS - Detection of early-stage hepatocellular carcinoma in asymptomatic HBsAg-seropositive individuals by liquid biopsy

#### Prognosis 

* **Progosis ctDNA**: 2019 JCO - Early Detection of Metastatic Relapse and Monitoring of Therapeutic Efficacy by Ultra-Deep Sequencing of Plasma Cell-Free DNA in Patients With Urothelial Bladder Carcinoma
* **Prognosis ctDNA**: 2019 JAMA Oncology - Analysis of Plasma Cell-Free DNA by Ultradeep Sequencing in Patients With Stages I to III Colorectal Cancer
* **Prognosis ctDNA**: 2019 Translational Med. - Personalized circulating tumor DNA analysis to detect residual disease after neoadjuvant therapy in breast cancer
* **Prognosis ctDNA**：2019 JAMA Oncology - Circulating Tumor DNA Analyses as Markers of Recurrence Risk and Benefit of Adjuvant Therapy for Stage III Colon Cancer
* **Liquid vs. tissue biopsy**： 2019 Nature Medicine - Liquid versus tissue biopsy for detecting acquired resistance and tumor heterogeneity in gastrointestinal cancers

### 3. Large-cohort Validation

> [PDFs](https://cloud.tsinghua.edu.cn/d/f72ee6992a1e4ec78044/?p=%2FBiomarker%20Panel%2FLarge-cohort%20Validation&mode=list)

#### 3.1 RNA Panel

* **miRNAs:** _**2020 Gut**_ - Development and validation of a serum microRNA biomarker panel for detecting gastric cancer in a high-risk population
* **miRNAs:** _**2020 PNAS**_ - Development of a serum miRNA panel for detection of early stage non-small cell lung cancer
* **miRNA7**: _**2011 JCO**_ - Jia Fan - Plasma MicroRNA Panel to Diagnose Hepatitis B Virus–Related Hepatocellular Carcinoma

